Verthermia, founded in 2012, is dedicated to advancing whole body hyperthermia (WBH) as a viable cancer therapy. The company's core mission is to harness the healing power of heat to treat cancer, with a current focus on ovarian cancer. Verthermia's innovative HEATT® technology emphasizes safety and patient well-being through meticulous monitoring and professional anesthesia, ensuring a non-invasive and pain-free treatment experience.
Verthermia's notable achievements include progressing to a Phase I clinical trial for ovarian cancer, demonstrating the potential of their HEATT® technology. By prioritizing patient safety and comfort, Verthermia aims to revolutionize cancer treatment and provide renewed hope to patients. Their impact is marked by the innovative application of hyperthermia in oncology, potentially offering a new, effective treatment modality for cancer patients worldwide.
